TABLE I.

Comparison of blocker impact on RIV for all HEK 293 constructs

Drug orderBasalaForskolinGlyH-101Forskolin+GlyH-101Forskolin+GlibenclamideGlyH-101+ForskolinGlibenclamide+Forskolin
Construct
SLC26A90.98 ± 0.030.96 ± 0.040.85 ± 0.020.83 ± 0.020.95 ± 0.02ntbnt
wtCFTR1.30 ± 0.050.98 ± 0.010.96 ± 0.04c0.42 ± 0.031.84 ± 0.020.35 ± 0.011.82 ± 0.03
SLC26A9 + wtCFTR1.04 ± 0.040.99 ± 0.010.84 ± 0.040.62 ± 0.051.41 ± 0.100.50 ± 0.071.40 ± 0.09
  • Order of agonist or blocker represents experimental additions. Each measurement represents an n ≥ 3.

  • a Basal values given are for cells subsequently exposed to forskolin.

  • b nt, not tested.

  • c CFTR was inactive with Im = −0.09 ± 0.27 pA/pF.